237 related articles for article (PubMed ID: 23279642)
1. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
[TBL] [Abstract][Full Text] [Related]
2. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.
Xiu P; Xu Z; Liu F; Li Z; Li T; Zou F; Sun X; Li J
Dig Dis Sci; 2014 Aug; 59(8):1798-809. PubMed ID: 24671452
[TBL] [Abstract][Full Text] [Related]
3. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway.
Huang G; Li L; Liang C; Yu F; Teng C; Pang Y; Wei T; Song J; Wang H; Liao X; Li Y; Yang J
Pharmacol Res Perspect; 2021 Feb; 9(1):e00720. PubMed ID: 33565716
[TBL] [Abstract][Full Text] [Related]
4. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis.
Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L
J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741
[TBL] [Abstract][Full Text] [Related]
5. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
Zhang J; Wu M; Xu Y; Song Q; Zheng W
Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
[TBL] [Abstract][Full Text] [Related]
6. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
7. Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Wang X; Zou F; Zhong J; Yue L; Wang F; Wei H; Yang G; Jin T; Dong X; Li J; Xiu P
J Cancer; 2018; 9(8):1403-1413. PubMed ID: 29721050
[No Abstract] [Full Text] [Related]
8. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
[TBL] [Abstract][Full Text] [Related]
9. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
10. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Int J Mol Med; 2018 May; 41(5):2893-2900. PubMed ID: 29436591
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
13. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression.
Wang Y; Wang X; Zhao H; Liang B; Du Q
J Chemother; 2012 Dec; 24(6):348-57. PubMed ID: 23174100
[TBL] [Abstract][Full Text] [Related]
14. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.
Ma L; Xu A; Kang L; Cong R; Fan Z; Zhu X; Huo N; Liu W; Xue C; Ji Q; Li W; Chu Z; Kang X; Wang Y; Sun Z; Han Y; Liu H; Gao X; Han J; You H; Zhao C; Xu X
Hepatology; 2021 Dec; 74(6):3213-3234. PubMed ID: 34322883
[TBL] [Abstract][Full Text] [Related]
15. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
16. Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway.
Naik PP; Mukhopadhyay S; Praharaj PP; Bhol CS; Panigrahi DP; Mahapatra KK; Patra S; Saha S; Panda AK; Panda K; Paul S; Aich P; Patra SK; Bhutia SK
Life Sci; 2021 Jan; 264():118722. PubMed ID: 33160989
[TBL] [Abstract][Full Text] [Related]
17. Secretory Clusterin Inhibits Dopamine Neuron Apoptosis in MPTP Mice by Preserving Autophagy Activity.
Zhu D; Zhang S; Wang X; Xiao C; Cui G; Yang X
Neuroscience; 2024 Mar; 540():38-47. PubMed ID: 38242280
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1.
Bu Y; Jia QA; Ren ZG; Zhang JB; Jiang XM; Liang L; Xue TC; Zhang QB; Wang YH; Zhang L; Xie XY; Tang ZY
PLoS One; 2014; 9(3):e89686. PubMed ID: 24632571
[TBL] [Abstract][Full Text] [Related]
19. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin.
Ma X; Bai Y
Mol Med Rep; 2012 Dec; 6(6):1433-7. PubMed ID: 23027041
[TBL] [Abstract][Full Text] [Related]
20. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
